COMMUNIQUÉS West-GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

26/03/2025 - 13:00

NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

26/03/2025 - 13:00

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]

NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference

26/03/2025 - 13:00

MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management [...]

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

26/03/2025 - 13:00

SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor [...]

Dewpoint Therapeutics announces upcoming presentations at AACR 2025

26/03/2025 - 13:00

Dewpoint will present two posters at AACR Condensate modulators (c-mods) demonstrate robust anti-tumor effects across multiple types of cancer C-mods modulate the oncogenic function of historically undruggable targets [...]

E-Star BioTech Announces Presentation During 2025 Annual Meeting of the American College of Cardiology

26/03/2025 - 13:00

“Differential Response Between African Americans and Non-African Americans with Resistant Hypertension to MANP, a Novel Guanylyl Cyclase-A Receptor Activator: A Phase 1b Clinical Trial” NEW YORK, March 26, 2025 (GLOBE [...]

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

26/03/2025 - 13:00

DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

26/03/2025 - 12:30

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 [...]

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

26/03/2025 - 12:30

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted [...]

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

26/03/2025 - 12:30

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc . (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs [...]

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

26/03/2025 - 12:30

Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; [...]

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

26/03/2025 - 12:30

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

26/03/2025 - 12:30

Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu Ratutrelvir, a main protease inhibitor [...]

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

26/03/2025 - 12:30

– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in [...]

Entourage Health Increases Senior Secured Credit Facility

26/03/2025 - 12:30

TORONTO, March 26, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. ( TSX-V: ENTG ) ( OTCQX: ETRGF ) ( FSE: 4WE ) (" Entourage " or the " Company "), a Canadian producer and distributor of award-winning cannabis products [...]

PurDentix Probiotic Supplement: Ingredients, Benefits, Reviews & Where to Buy

26/03/2025 - 12:11

AURORA, Colo., March 26, 2025 (GLOBE NEWSWIRE) -- Maintaining optimal oral health is more crucial than ever in today's unhealthy world. Many struggle with gum disease, tooth decay, and oral hygiene, leading to a growing [...]

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

26/03/2025 - 12:00

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDNA113, will also be [...]

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

26/03/2025 - 12:00

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track [...]

Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe

26/03/2025 - 12:00

ADOPT Study Findings Highlight Nanox.AI’s Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: [...]